Biofrontera to Showcase Actinic Keratoses and Impetigo Treatments at the 2022 American Academy of Dermatology Annual Meeting
March 17 2022 - 10:20AM
Biofrontera
Inc. (Nasdaq: BFRI),
a biopharmaceutical company specializing in the commercialization
of dermatologic products, announced today it will be hosting a
booth showcasing its innovative, FDA-approved products at the 2022
American Academy of Dermatology (AAD) Annual Meeting taking place
March 25-29, 2022 at the Boston Convention and Exhibition Center.
“We look forward to a strong presence at the
year’s largest and most prestigious dermatology conference
following encouraging momentum with our clinical studies and our
commercial footprint. We anticipate a busy booth and look forward
to connecting with dermatologists, practitioners and
dermatology-focused service providers as we grow our trusted
brands. Showcasing our portfolio on the dermatology community’s
premier global stage offers us tremendous visibility and
facilitates our ability to demonstrate the benefits of photodynamic
therapy (PDT) for the treatment of actinic keratoses (AK), one of
the most common precancerous skin conditions,” stated Erica Monaco,
Chief Executive Officer of Biofrontera Inc.
Members of Biofrontera Inc.’s management team,
including Ms. Monaco and Hermann Lübbert, Executive Chairman of
Biofrontera Inc., will be in attendance meeting with academic and
clinical dermatologists, prospective customers and industry key
opinion leaders. The Biofrontera Inc. booth (#469) will feature
educational and commercial information on its products including
the FDA-approved flagship drug Ameluz® (aminolevulinic acid
hydrochloride gel, 10%), which is used in combination with the
RhodoLED® lamp series for the treatment of AK, and the topical
antibiotic drug Xepi® (ozenoxacin cream, 1%), FDA-approved for the
treatment of impetigo. In collaboration with dermatologists,
Biofrontera is fully committed to advancing treatment options and
patient care.
The AAD Annual Meeting is the world’s largest
scientific meeting for dermatologists, with an average attendance
of approximately 18,000 including approximately 10,000 medical
personnel.
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based
biopharmaceutical company commercializing a portfolio of
pharmaceutical products for the treatment of dermatological
conditions with a focus on PDT and topical antibiotics. The
Company’s licensed products are used for the treatment of actinic
keratoses, which are pre-cancerous skin lesions, as well as
impetigo, a bacterial skin infection. For more information, visit
www.biofrontera-us.com.
Forward-Looking Statements
Certain statements in this press release may
constitute "forward-looking statements" within the meaning of the
United States Private Securities Litigation Reform Act of 1995, as
amended to date. These statements include, but are not limited to,
statements relating to the expected trading commencement and
closing dates. We have based these forward-looking statements on
our current expectations and projections about future events,
nevertheless, actual results or events could differ materially from
the plans, intentions and expectations disclosed in, or implied by,
the forward-looking statements we make. These risks and
uncertainties, many of which are beyond our control, including, but
not limited to, the impact of extraordinary external events, such
as the current COVID-19 pandemic; any changes in the Company’s
relationship with the Licensor; the Company’s ability to achieve
and sustain profitability; whether the current global disruptions
in supply chains will impact the Company’s ability to obtain and
distribute its licensed products; changes in the practices of
healthcare providers, including any changes to the coverage,
reimbursement and pricing for procedures using the Company’s
licensed products; the uncertainties inherent in the initiation and
conduct of clinical trials; availability and timing of data from
clinical trials; whether results of earlier clinical trials or
trials of Ameluz® in combination with BF-RhodoLED® in different
disease indications or product applications will be indicative of
the results of ongoing or future trials; uncertainties associated
with regulatory review of clinical trials and applications for
marketing approvals; whether the market opportunity for Ameluz® in
combination with BF-RhodoLED® is consistent with the Company’s
expectations; whether the Company will be able to successfully
transition to a public company operating independently of
Biofrontera AG; the Company’s ability to retain and hire key
personnel; the sufficiency of cash resources and need for
additional financing and other factors that may be disclosed in the
Company’s filings with the SEC, which can be obtained on the SEC
website at www.sec.gov. Readers are cautioned not to place undue
reliance on the forward-looking statements, which speak only as of
the date on which they are made and reflect management's current
estimates, projections, expectations and beliefs. The company does
not plan to update any such forward-looking statements and
expressly disclaims any duty to update the information contained in
this press release except as required by law.
Contacts:
Biofrontera Inc.Anke zur
Mühlen+1 781 486 1539us-ir@biofrontera.com
LHA Investor RelationsTirth T.
Patel+1 212 201 6614tpatel@lhai.com
# # #
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Sep 2023 to Sep 2024